Published in Drug Week, July 30th, 2004
The approval was based on the results of the RHYTHM (Resynchronization HemodYnamic Treatment for Heart Failure Management) ICD study, which demonstrated a significant improvement in peak oxygen consumption, exercise duration, NYHA Class, and quality of life in patients treated with CRT.
Full U.S. market release of St. Jude Medical's high-voltage cardiac...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.